{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:19:27Z","timestamp":1791519567542,"version":"4.3.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":41,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chemosensitivity testing, including collagen gel droplet-embedded culture drug sensitivity test, has proven to be a useful tool in therapeutic decision-making. This retrospective analysis investigated chemosensitivity testing of peritoneal metastases collected during cytoreductive surgery (CRS), and its impact on survival in patients with colorectal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with peritoneal metastasis from colorectal cancer who underwent CRS with or without hyperthermic intraperitoneal chemotherapy (HIPEC) between November 2008 and October 2014 were included. The growth inhibition rate was expressed as the ratio between the image density after treatment (T) and that before treatment (control, C). Tumours with a reduction in T\/C ratio of less than 20 per cent were defined as resistant and those with a reduction of 20 per cent or more as sensitive. Groups were compared for overall (OS) and disease-free (DFS) survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 84 eligible patients, 81 received neoadjuvant chemotherapy (NACT), including 56 patients with an oxaliplatin-based regimen. Mean(s.d.) follow-up was 23\u00b74(22\u00b79) months. The median overall survival of all patients was 19\u00b70 (i.q.r. 5\u00b77\u201336\u00b71) months, with a progression-free survival time of 10\u00b71 (4\u00b75\u201317\u00b70) months. Patients who received oxaliplatin-based NACT had significantly altered chemosensitivity to oxaliplatin; only 20 of 51 such patients showed chemosensitivity to oxaliplatin compared with 16 of 24 who did not undergo oxaliplatin-based NACT (P\u00a0=\u00a00\u00b7046). However, patients who showed chemoresistance to oxaliplatin had similar OS to those with chemosensitivity (18\u00b78 versus 18\u00b71\u2009months; P\u00a0=\u00a00\u00b7835). The choice of HIPEC agents in patients who received oxaliplatin-based NACT did not significantly influence survival (oxaliplatin versus mitomycin C: median OS 20\u00b76 (10\u00b79\u201324\u00b78) versus 19\u00b70 (10\u00b75\u201334\u00b76) months, P\u2009=\u00a00\u00b7811; DFS 6\u00b76 (2\u00b78\u201325\u00b77) versus 9\u00b73 (4\u00b71\u201313\u00b79) months, P\u2009=\u00a00\u00b7191).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients who had oxaliplatin-based NACT showed a higher rate of chemoresistance to oxaliplatin at the time of CRS and HIPEC. The impact of chemosensitivity testing on OS remains unclear and needs further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/bjsopen\/zraa075","type":"journal-article","created":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T12:42:10Z","timestamp":1618144930000},"source":"Crossref","is-referenced-by-count":19,"title":["Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study"],"prefix":"10.1093","volume":"5","author":[{"given":"A","family":"Prabhu","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology Thangam Cancer Centre, Namakkal India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-2584","authenticated-orcid":false,"given":"A","family":"Brandl","sequence":"additional","affiliation":[{"name":"Digestive Unit Champalimaud Foundation, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wakama","sequence":"additional","affiliation":[{"name":"Department of Surgery Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Sako","sequence":"additional","affiliation":[{"name":"Non-Profit Organization to Support Peritoneal Surface Malignancy Treatment Japanese\/Asian School of Peritoneal Surface Oncology, Kyoto Japan"},{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kishiwada, Tokushukai Hospital Kishiwada Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kishiwada, Tokushukai Hospital Kishiwada Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mizumoto","sequence":"additional","affiliation":[{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kusatsu General Hospital Shiga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Takao","sequence":"additional","affiliation":[{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kusatsu General Hospital Shiga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kusatsu General Hospital Shiga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Motoi","sequence":"additional","affiliation":[{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kusatsu General Hospital Shiga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Liu","sequence":"additional","affiliation":[{"name":"Non-Profit Organization to Support Peritoneal Surface Malignancy Treatment Japanese\/Asian School of Peritoneal Surface Oncology, Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-4106","authenticated-orcid":false,"given":"Y","family":"Yonemura","sequence":"additional","affiliation":[{"name":"Non-Profit Organization to Support Peritoneal Surface Malignancy Treatment Japanese\/Asian School of Peritoneal Surface Oncology, Kyoto Japan"},{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kishiwada, Tokushukai Hospital Kishiwada Japan"},{"name":"Department of Regional Cancer Therapy Peritoneal Surface Malignancy Centre, Kusatsu General Hospital Shiga Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"2021071008015291800_zraa075-B1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen","year":"2014","journal-title":"Ann Oncol"},{"key":"2021071008015291800_zraa075-B2","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1245\/s10434-019-07294-y","article-title":"Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study","volume":"26","author":"Hentzen","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2021071008015291800_zraa075-B3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Ann Surg"},{"key":"2021071008015291800_zraa075-B4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann Surg"},{"key":"2021071008015291800_zraa075-B5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.24290","article-title":"Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort","volume":"114","author":"Froysnes","year":"2016","journal-title":"J Surg Oncol"},{"key":"2021071008015291800_zraa075-B6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","article-title":"Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review","volume":"100","author":"Baratti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021071008015291800_zraa075-B7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021071008015291800_zraa075-B8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejso.2012.03.008","article-title":"Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy","volume":"38","author":"Klaver","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"2021071008015291800_zraa075-B9","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.3747\/co.26.4217","article-title":"Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer","volume":"26","author":"Bazarbashi","year":"2019","journal-title":"Curr Oncol"},{"key":"2021071008015291800_zraa075-B10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s005340050044","article-title":"A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility","volume":"5","author":"Yasuda","year":"1998","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2021071008015291800_zraa075-B11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00280-013-2189-7","article-title":"Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer","volume":"72","author":"Takebayashi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021071008015291800_zraa075-B12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ijc.10208","article-title":"Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers","volume":"98","author":"Takamura","year":"2002","journal-title":"Int J Cancer"},{"key":"2021071008015291800_zraa075-B13","first-page":"1027","article-title":"An in vitro chemosensitivity test for gastric cancer using collagen gel droplet embedded culture","volume":"7","author":"Hanatani","year":"2000","journal-title":"Oncol Rep"},{"key":"2021071008015291800_zraa075-B14","first-page":"279","article-title":"Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response","volume":"8","author":"Higashiyama","year":"2001","journal-title":"Oncol Rep"},{"key":"2021071008015291800_zraa075-B15","first-page":"307","article-title":"Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer","volume":"12","author":"Yabushita","year":"2004","journal-title":"Oncol Rep"},{"key":"2021071008015291800_zraa075-B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2021071008015291800_zraa075-B17","first-page":"449","article-title":"An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures","volume":"11","author":"Kobayashi","year":"1997","journal-title":"Int J Oncol"},{"key":"2021071008015291800_zraa075-B18","first-page":"1933","article-title":"Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness","volume":"22","author":"Kobayashi","year":"1995","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021071008015291800_zraa075-B19","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1073\/pnas.76.7.3401","article-title":"Sustained growth and three-dimensional organization of primary mammary tumor epithelial cells embedded in collagen gels","volume":"76","author":"Yang","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021071008015291800_zraa075-B20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/978-3-642-19022-3_5","article-title":"Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness","volume":"161","author":"Kobayashi","year":"2003","journal-title":"Recent Results Cancer Res"},{"key":"2021071008015291800_zraa075-B21","doi-asserted-by":"crossref","first-page":"LBA3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021071008015291800_zraa075-B22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/1535-7163.MCT-18-0128","article-title":"A chemosensitivity study of colorectal cancer using xenografts of patient-derived tumor-initiating cells","volume":"17","author":"Maekawa","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2021071008015291800_zraa075-B23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molonc.2013.09.004","article-title":"miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase","volume":"8","author":"Zhou","year":"2014","journal-title":"Mol Oncol"},{"key":"2021071008015291800_zraa075-B24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/cancers12030697","article-title":"Oxaliplatin-induced DHX9 phosphorylation promotes oncogenic circular RNA CCDC66 expression and development of chemoresistance","volume":"12","author":"Lin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2021071008015291800_zraa075-B25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/1471-2407-13-435","article-title":"Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer","volume":"13","author":"Cashin","year":"2013","journal-title":"BMC Cancer"},{"key":"2021071008015291800_zraa075-B26","first-page":"6045","article-title":"Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test","volume":"14","author":"Ochiai","year":"2017","journal-title":"Oncol Lett"},{"key":"2021071008015291800_zraa075-B27","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021071008015291800_zraa075-B28","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021071008015291800_zraa075-B29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021071008015291800_zraa075-B30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00595-019-01842-5","article-title":"Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer","volume":"49","author":"Ariake","year":"2019","journal-title":"Surg Today"},{"key":"2021071008015291800_zraa075-B31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jso.24906","article-title":"5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer","volume":"117","author":"Murata","year":"2018","journal-title":"J Surg Oncol"},{"key":"2021071008015291800_zraa075-B32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/jcm7120567","article-title":"Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer","volume":"7","author":"Yurttas","year":"2018","journal-title":"J Clin Med"},{"key":"2021071008015291800_zraa075-B33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/2472630316686297","article-title":"Predictive value of ex vivo chemosensitivity assays for individualized cancer chemotherapy: a meta-analysis","volume":"22","author":"Blom","year":"2017","journal-title":"SLAS Technol"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bjsopen\/article-pdf\/5\/2\/zraa075\/38891155\/zraa075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjsopen\/article-pdf\/5\/2\/zraa075\/38891155\/zraa075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:08:45Z","timestamp":1671844125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zraa075\/6220267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zraa075","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2021,3]]},"article-number":"zraa075"}}